aTYR PHARMA (ATYR) EPS (Basic) Growth (3y) (2017 - 2026)
Powered by 
Analysis
aTYR PHARMA (ATYR) EPS (Basic) Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 19.50% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -129.90% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 6.85% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 11.71% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 18.44% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 86.03% |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 36.73% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -45.60% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - | 23.46% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 23.46% |
| Mar 31, 2026 | 26.94% |
| Dec 31, 2025 | 17.14% |
| Sep 30, 2025 | 16.08% |
| Jun 30, 2025 | 20.58% |
| Mar 31, 2025 | 26.64% |
| Dec 31, 2024 | 22.80% |
| Sep 30, 2024 | 17.48% |
| Jun 30, 2024 | 28.21% |
| Mar 31, 2024 | 20.92% |
| Dec 31, 2023 | 17.97% |
| Sep 30, 2023 | 31.40% |
| Jun 30, 2023 | 28.41% |
| Mar 31, 2023 | -46.14% |
| Dec 31, 2022 | 46.00% |
| Sep 30, 2022 | 31.19% |
| Jun 30, 2022 | 36.23% |
| Mar 31, 2022 | 42.42% |
| Dec 31, 2021 | 45.04% |
| Sep 30, 2021 | 48.49% |